$INBP
INTEGRATED BIOPHARMA INC

2023 Q3 Form 10-K Financial Statement

#000143774923026022 Filed on September 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2023
Revenue $12.92M $12.99M $50.67M
YoY Change 4.78% -2.09% -9.91%
Cost Of Revenue $12.08M $12.01M $46.61M
YoY Change 6.66% 1.17% -6.2%
Gross Profit $832.0K $990.0K $4.061M
YoY Change -16.55% -29.08% -38.02%
Gross Profit Margin 6.44% 7.62% 8.01%
Selling, General & Admin $886.0K $910.0K $3.941M
YoY Change -8.38% -5.01% 3.52%
% of Gross Profit 106.49% 91.92% 97.05%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $77.00K $80.00K $351.0K
YoY Change -12.5% -10.11% 4.46%
% of Gross Profit 9.25% 8.08% 8.64%
Operating Expenses $886.0K $910.0K $3.941M
YoY Change -8.38% -5.01% 3.52%
Operating Profit -$54.00K $80.00K $120.0K
YoY Change -280.0% -81.74% -95.63%
Interest Expense -$8.000K -$10.00K $52.00K
YoY Change -161.54% -67.74% -59.38%
% of Operating Profit -12.5% 43.33%
Other Income/Expense, Net $8.000K $20.00K -$20.00K
YoY Change -157.14% -86.49%
Pretax Income -$46.00K $80.00K $100.0K
YoY Change -387.5% -80.34% -96.15%
Income Tax $13.00K $40.00K $134.0K
% Of Pretax Income 50.0% 134.0%
Net Earnings -$59.00K $40.00K -$34.00K
YoY Change 68.57% -97.32% -100.89%
Net Earnings / Revenue -0.46% 0.31% -0.07%
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 29.95M 29.93M 29.95M
Diluted Shares Outstanding 29.97M 29.95M

Balance Sheet

Concept 2023 Q3 2023 Q2 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.590M $1.320M $1.320M
YoY Change 121.75% 298.79% 298.79%
Cash & Equivalents $2.594M $1.316M
Short-Term Investments
Other Short-Term Assets $482.0K $284.0K $280.0K
YoY Change -6.59% -19.32% -20.45%
Inventory $10.51M $10.26M $10.26M
Prepaid Expenses
Receivables $4.172M $4.511M $4.510M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $17.76M $16.37M $16.37M
YoY Change 4.08% -1.53% -1.54%
LONG-TERM ASSETS
Property, Plant & Equipment $1.636M $1.653M $4.280M
YoY Change -11.57% -13.46% 13.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.780M $4.780M $4.780M
YoY Change -0.52% -1.38% -1.38%
Total Long-Term Assets $8.883M $9.059M $9.060M
YoY Change -4.49% 5.04% 5.06%
TOTAL ASSETS
Total Short-Term Assets $17.76M $16.37M $16.37M
Total Long-Term Assets $8.883M $9.059M $9.060M
Total Assets $26.64M $25.43M $25.43M
YoY Change 1.05% 0.72% 0.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.536M $2.266M $2.270M
YoY Change 0.2% -29.39% -29.26%
Accrued Expenses $2.620M $2.520M $2.520M
YoY Change 16.81% 31.18% 31.18%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Long-Term Debt Due $40.00K $42.00K $40.00K
YoY Change -4.76% 31.25% 25.0%
Total Short-Term Liabilities $6.197M $4.828M $4.830M
YoY Change 6.59% -8.27% -8.23%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $7.000K $10.00K
YoY Change -100.0% -86.79% -81.13%
Other Long-Term Liabilities $1.560M $1.740M $1.740M
YoY Change -17.46% 28.04% 28.04%
Total Long-Term Liabilities $1.560M $7.000K $1.750M
YoY Change 3900.0% -86.79% 23.94%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.197M $4.828M $4.830M
Total Long-Term Liabilities $1.560M $7.000K $1.750M
Total Liabilities $7.756M $6.570M $6.570M
YoY Change 0.17% -1.57% -1.57%
SHAREHOLDERS EQUITY
Retained Earnings -$32.40M -$32.34M
YoY Change 0.18% 0.11%
Common Stock $60.00K $60.00K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $18.89M $18.86M $18.86M
YoY Change
Total Liabilities & Shareholders Equity $26.64M $25.43M $25.43M
YoY Change 1.05% 0.72% 0.71%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2023
OPERATING ACTIVITIES
Net Income -$59.00K $40.00K -$34.00K
YoY Change 68.57% -97.32% -100.89%
Depreciation, Depletion And Amortization $77.00K $80.00K $351.0K
YoY Change -12.5% -10.11% 4.46%
Cash From Operating Activities $1.313M -$1.190M $1.232M
YoY Change 32.36% -144.03% -69.89%
INVESTING ACTIVITIES
Capital Expenditures $38.00K $20.00K $116.0K
YoY Change -24.0% -157.14% -76.13%
Acquisitions
YoY Change
Other Investing Activities $10.00K $10.00K
YoY Change -52.38%
Cash From Investing Activities -$38.00K -$20.00K -$111.0K
YoY Change -24.0% -42.86% -76.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $3.000K -10.00K -$136.0K
YoY Change -102.86% -99.62% -96.12%
NET CHANGE
Cash From Operating Activities $1.313M -1.190M $1.232M
Cash From Investing Activities -$38.00K -20.00K -$111.0K
Cash From Financing Activities $3.000K -10.00K -$136.0K
Net Change In Cash $1.278M -1.220M $985.0K
YoY Change 52.69% -1920.9% 714.05%
FREE CASH FLOW
Cash From Operating Activities $1.313M -$1.190M $1.232M
Capital Expenditures $38.00K $20.00K $116.0K
Free Cash Flow $1.275M -$1.210M $1.116M
YoY Change 35.35% -144.19% -69.04%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2477939
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.002
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.002
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29984510
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29984510
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29949610
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29949610
CY2023Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
34900
CY2022Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
34900
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P3Y
CY2023 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 pure
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-31668
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
22-2407475
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
225 Long Ave.
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Hillside
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07205
CY2023 dei City Area Code
CityAreaCode
888
CY2023 dei Local Phone Number
LocalPhoneNumber
319-6962
CY2023 dei Security12g Title
Security12gTitle
Common Stock, $.002 par value per share
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Public Float
EntityPublicFloat
3258720 usd
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29949610
CY2023 dei Auditor Firm
AuditorFirmId
688
CY2023 dei Auditor Name
AuditorName
Marcum LLP
CY2023 dei Auditor Location
AuditorLocation
East Hanover, New Jersey
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
50672000 usd
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
56246000 usd
CY2023 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
46611000 usd
CY2022 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
49694000 usd
CY2023 us-gaap Gross Profit
GrossProfit
4061000 usd
CY2022 us-gaap Gross Profit
GrossProfit
6552000 usd
CY2023 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3941000 usd
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3807000 usd
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
120000 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
2745000 usd
CY2023 us-gaap Interest Expense
InterestExpense
52000 usd
CY2022 us-gaap Interest Expense
InterestExpense
128000 usd
CY2023 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
27000 usd
CY2022 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-55000 usd
CY2023 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-35000 usd
CY2022 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0 usd
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
40000 usd
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
35000 usd
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-20000 usd
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-148000 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
100000 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2597000 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
134000 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1241000 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-34000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
3838000 usd
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.12
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29949610
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29843386
CY2023 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29949610
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32321326
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1316000 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
331000 usd
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4511000 usd
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4888000 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
10261000 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
11055000 usd
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
284000 usd
CY2022Q2 us-gaap Other Assets Current
OtherAssetsCurrent
352000 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
16372000 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
16626000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1653000 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1910000 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2623000 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1867000 usd
CY2023Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
4726000 usd
CY2022Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
4798000 usd
CY2023Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
57000 usd
CY2022Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
49000 usd
CY2023Q2 us-gaap Assets
Assets
25431000 usd
CY2022Q2 us-gaap Assets
Assets
25250000 usd
CY2023Q2 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
0 usd
CY2022Q2 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
101000 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2266000 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3209000 usd
CY2023Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1632000 usd
CY2022Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1411000 usd
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
42000 usd
CY2022Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
32000 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
888000 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
510000 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4828000 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
5263000 usd
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
7000 usd
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
53000 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1735000 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1359000 usd
CY2023Q2 us-gaap Liabilities
Liabilities
6570000 usd
CY2022Q2 us-gaap Liabilities
Liabilities
6675000 usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
60000 usd
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
60000 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
51239000 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
50919000 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32339000 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32305000 usd
CY2023Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
99000 usd
CY2022Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
99000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
18861000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
18575000 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25431000 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25250000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
14334000 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
369000 usd
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
34000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
3838000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
18575000 usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
320000 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-34000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
18861000 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-34000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
3838000 usd
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
803000 usd
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
498000 usd
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
351000 usd
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
336000 usd
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
72000 usd
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1530000 usd
CY2023 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
12000 usd
CY2022 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
21000 usd
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
320000 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
369000 usd
CY2023 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
27000 usd
CY2022 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-55000 usd
CY2023 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-35000 usd
CY2022 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-0 usd
CY2023 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
3000 usd
CY2022 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
13000 usd
CY2023 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
1000 usd
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
22000 usd
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-374000 usd
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-875000 usd
CY2023 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-794000 usd
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-640000 usd
CY2023 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-34000 usd
CY2022 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
84000 usd
CY2023 inbp Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-804000 usd
CY2022 inbp Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-501000 usd
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-921000 usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-218000 usd
CY2023 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
221000 usd
CY2022 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-199000 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1232000 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
4091000 usd
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
116000 usd
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
486000 usd
CY2023 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
4000 usd
CY2022 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
0 usd
CY2023 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1000 usd
CY2022 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
21000 usd
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-111000 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-465000 usd
CY2023 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
101000 usd
CY2022 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
2073000 usd
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
34000 usd
CY2023 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
-0 usd
CY2022 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1466000 usd
CY2023 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
35000 usd
CY2022 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
-0 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-136000 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3505000 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
985000 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
121000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
331000 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
210000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1316000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
331000 usd
CY2023 us-gaap Interest Paid Net
InterestPaidNet
41000 usd
CY2022 us-gaap Interest Paid Net
InterestPaidNet
113000 usd
CY2023 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2022 us-gaap Income Taxes Paid
IncomeTaxesPaid
471000 usd
CY2023 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 usd
CY2022 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
22000 usd
CY2023 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
0 usd
CY2022 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
85000 usd
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1560000 usd
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
CY2023 inbp Trade In Value On Likekind Exchanges
TradeInValueOnLikekindExchanges
0 usd
CY2022 inbp Trade In Value On Likekind Exchanges
TradeInValueOnLikekindExchanges
7000 usd
CY2023 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;"><b><i>Reclassifications. </i></b>Certain prior year amounts have been reclassified to conform to the current year presentation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;"><b><i>Use of Estimates.</i></b> The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are <em style="font: inherit;">not</em> readily apparent from other sources. The most significant estimates include:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 18pt;">●    sales returns and allowances;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 18pt;">●    allowance for doubtful accounts;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 18pt;">●    inventory valuation;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 18pt;">●    valuation and recoverability of long-lived assets;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 18pt;">●    income taxes and valuation allowance on deferred income taxes, and;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 18pt;">●    accruals for, and the probability of, the outcome of current litigation, if any.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;">On a continual basis, management reviews its estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such reviews, and if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b></b></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 18pt;"></p>
CY2022 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-55000 usd
CY2022Q2 us-gaap Investment Owned At Fair Value
InvestmentOwnedAtFairValue
12000 usd
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7444000 usd
CY2021Q2 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0 usd
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9422000 usd
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9354000 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7769000 usd
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
37000 usd
CY2022Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
85000 usd
CY2021 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 usd
CY2008Q3 inbp Cost Method Investment Ownership Percentage
CostMethodInvestmentOwnershipPercentage
0.06 pure
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
2562000 usd
CY2023 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-35000 usd
CY2022 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-0 usd
CY2023 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
27000 usd
CY2023Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
6859000 usd
CY2022Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
7586000 usd
CY2023Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2148000 usd
CY2022Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1759000 usd
CY2023Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1254000 usd
CY2022Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1440000 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
10261000 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
11055000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1653000 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1910000 usd
CY2023 us-gaap Depreciation
Depreciation
351000 usd
CY2022 us-gaap Depreciation
Depreciation
336000 usd
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
0 usd
CY2022Q2 us-gaap Long Term Debt
LongTermDebt
101000 usd
CY2023 us-gaap Interest Expense Subordinated Notes And Debentures
InterestExpenseSubordinatedNotesAndDebentures
12000 usd
CY2022 us-gaap Interest Expense Subordinated Notes And Debentures
InterestExpenseSubordinatedNotesAndDebentures
21000 usd
CY2023 us-gaap Interest Expense Other
InterestExpenseOther
0 usd
CY2022 us-gaap Interest Expense Other
InterestExpenseOther
4000 usd
CY2023 us-gaap Interest Expense
InterestExpense
52000 usd
CY2022 us-gaap Interest Expense
InterestExpense
128000 usd
CY2023Q2 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
0 usd
CY2022Q2 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
3000 usd
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-110000 usd
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-600000 usd
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-61000 usd
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-289000 usd
CY2023 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
55000 usd
CY2022 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
2106000 usd
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-18000 usd
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
24000 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
134000 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1241000 usd
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.551 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.115 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-1.660 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.046 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
2.012 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.856 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.621 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.006 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation Disposition Of Business
EffectiveIncomeTaxRateReconciliationDispositionOfBusiness
-0.184 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Disposition Of Business
EffectiveIncomeTaxRateReconciliationDispositionOfBusiness
0 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.126 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.001 pure
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-1.34 pure
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.478 pure
CY2023Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
5105000 usd
CY2022Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
5166000 usd
CY2023Q2 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
678000 usd
CY2022Q2 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
485000 usd
CY2023Q2 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
139000 usd
CY2022Q2 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
157000 usd
CY2023Q2 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
180000 usd
CY2022Q2 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
149000 usd
CY2023Q2 us-gaap Deferred Tax Assets Derivative Instruments
DeferredTaxAssetsDerivativeInstruments
337000 usd
CY2022Q2 us-gaap Deferred Tax Assets Derivative Instruments
DeferredTaxAssetsDerivativeInstruments
296000 usd
CY2023Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1435000 usd
CY2022Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1141000 usd
CY2023Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
4726000 usd
CY2022Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
4798000 usd
CY2021Q2 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0 usd
CY2021Q2 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0 usd
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2023Q2 us-gaap Share Price
SharePrice
0.41
CY2023 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
81000 usd
CY2022 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
86000 usd
CY2022Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2022Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
1949000 usd
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
650000 usd
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
650000 usd
CY2023 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
12000 usd
CY2022 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
3000 usd
CY2023 inbp Finance Lease Expense
FinanceLeaseExpense
12000 usd
CY2022 inbp Finance Lease Expense
FinanceLeaseExpense
3000 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2623000 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
888000 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1735000 usd
CY2023Q2 inbp Lease Commitment Amount
LeaseCommitmentAmount
2830000 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1867000 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
510000 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1359000 usd
CY2022Q2 inbp Lease Commitment Amount
LeaseCommitmentAmount
2004000 usd
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
461000 usd
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1002000 usd
CY2022 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
486000 usd
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
989000 usd
CY2023 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
0 usd
CY2023 inbp Repayments Of Long Term Capital Lease Obligations Including Interest
RepaymentsOfLongTermCapitalLeaseObligationsIncludingInterest
35000 usd
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
650000 usd
CY2022 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
0 usd
CY2022 inbp Repayments Of Long Term Capital Lease Obligations Including Interest
RepaymentsOfLongTermCapitalLeaseObligationsIncludingInterest
0 usd
CY2023Q2 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
42000 usd
CY2023Q2 inbp Lessee Operating And Finance Lease Liability To Be Paid Year One
LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearOne
1030000 usd
CY2023Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
7000 usd
CY2023Q2 inbp Lessee Operating And Finance Lease Liability To Be Paid Year Two
LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearTwo
998000 usd
CY2023Q2 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
0 usd
CY2023Q2 inbp Lessee Operating And Finance Lease Liability To Be Paid Year Three
LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearThree
640000 usd
CY2023Q2 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
0 usd
CY2023Q2 inbp Lessee Operating And Finance Lease Liability To Be Paid Year Four
LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFour
148000 usd
CY2023Q2 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
0 usd
CY2023Q2 inbp Lessee Operating And Finance Lease Liability To Be Paid Year Five
LesseeOperatingAndFinanceLeaseLiabilityToBePaidYearFive
63000 usd
CY2023Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
49000 usd
CY2023Q2 inbp Lessee Operating And Finance Lease Liability To Be Paid Total
LesseeOperatingAndFinanceLeaseLiabilityToBePaidTotal
2879000 usd
CY2023Q2 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
-0 usd
CY2023Q2 inbp Lessee Operating And Finance Lease Liability Undiscounted Excess Amount
LesseeOperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount
207000 usd
CY2023Q2 inbp Lessee Operating And Finance Lease Total
LesseeOperatingAndFinanceLeaseTotal
2672000 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
6823569
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3916666
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.26
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
764700
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.85
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
146333
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.23
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
44700
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.53
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
46400
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.47
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4443933
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.36
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
527000
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.42
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
594649
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.46
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4376284
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.35
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3524500
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.26
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3626551
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.30
CY2023 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
0.09
CY2023 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
1.05
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4376284
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3626551
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.30
CY2023 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
50672000 usd
CY2023 us-gaap Gross Profit
GrossProfit
4061000 usd
CY2023 us-gaap Depreciation
Depreciation
351000 usd
CY2023 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
116000 usd
CY2023Q2 us-gaap Assets
Assets
25431000 usd
CY2022 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
56246000 usd
CY2022 us-gaap Gross Profit
GrossProfit
6552000 usd
CY2022 us-gaap Depreciation
Depreciation
336000 usd
CY2022Q2 us-gaap Assets
Assets
25250000 usd

Files In Submission

Name View Source Status
0001437749-23-026022-index-headers.html Edgar Link pending
0001437749-23-026022-index.html Edgar Link pending
0001437749-23-026022.txt Edgar Link pending
0001437749-23-026022-xbrl.zip Edgar Link pending
ex_524429.htm Edgar Link pending
ex_524430.htm Edgar Link pending
ex_524431.htm Edgar Link pending
ex_524432.htm Edgar Link pending
ex_524433.htm Edgar Link pending
ex_524434.htm Edgar Link pending
ex_567561.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
inbp-20230630.xsd Edgar Link pending
inbp20230630_10k.htm Edgar Link pending
MetaLinks.json Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
inbp-20230630_lab.xml Edgar Link unprocessable
inbp-20230630_def.xml Edgar Link unprocessable
inbp-20230630_cal.xml Edgar Link unprocessable
inbp-20230630_pre.xml Edgar Link unprocessable
inbp20230630_10k_htm.xml Edgar Link completed
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending